首页> 外文期刊>World Journal of Surgery: Official Journal of the Societe Internationale de Chirurgie, Collegium Internationale Chirurgiae Digestivae, and of the International Association of Endocrine Surgeons >Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cutoff Value
【24h】

Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cutoff Value

机译:根据最佳术前碳水化合物抗原19-9截止值的抗原肝胆管癌的外科手术指示

获取原文
获取原文并翻译 | 示例
           

摘要

Background The indication of surgery in intrahepatic cholangiocarcinoma (ICC) patients with lymph node metastasis (LNM), macroscopic periductal infiltration (PI), and intrahepatic metastasis (IM) remains unclear. Methods Patients who underwent resection for mass-forming (MF) dominant ICC and unresected patients caused by LNM, IM, or locally advanced tumors (UR group) were enrolled. The significance of CA19-9 was investigated in advanced ICC. Results Seventy-three patients who underwent resection and 20 UR patients were analyzed. Using the minimum p value approach based on the overall survival, the optimal CA19-9 cutoff value was 300?U/mL. The OS of the patients with CA19-9?
机译:背景技术肝内胆管癌(ICC)淋巴结转移患者(LNM),宏观蠕动浸润(PI)和肝内转移(IM)的患者患者患者的手术迹象仍不清楚。方法招聘患者患有大规模成分(MF)占主导地位(MF)的患者和由LNM,IM或局部晚期肿瘤(UR组)的未表明患者进行注册。在高级ICC中调查了CA19-9的重要性。结果分析了七十三名接受切除和20例患者的患者。使用基于整体存活的最小P值方法,最佳CA19-9截止值为300?U / mL。 CA19-9患者的OS?<?37?U / ml(n?= 26; MST,49.6?月)和37-300?U / ml(n?= 28; MST,45.1?月)可比较(p?= 0.842);然而,CA19-9患者的OS?= 37-300?U / ml明显优于CA19-9?≥?300?U / ml(n?=?19; MST,15.3?月; p?300?300?U / ml,MF?+βpi和IM​​与OS独立相关。CA19-9患者的OS?<?300?U / ml开发的LNM(MST,34.0?月),MF?+?PI(MST,32.9个半月),或IM(MST,35.2个半月)所需主要血管切除术(MST,45.1?个月)明显高于那些CA19-9?≥?300更好,或者谁?u / ml开发的lnm(mst,8.7个月; p?= 0.005),mf?+ pi(mst,7.5?月; p?=Δ040),或Im(mst,8.7?月; p ?=?0.001),或者需要主要血管切除(MST,14.8个月; P?= 0.015);他们的预后与UR组相似。即使患者有ICC开发LNM,PI或IM,也是需要主要的血管切除,可以针对CA19-9患者表明手术切除术,用于患者的患者。然而,应在CA19-9患者中仔细确定佐剂治疗或切除的适应症?≥? 300?U / ml。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号